{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:11:12Z","timestamp":1788811872610,"version":"build-2803163510"},"reference-count":131,"publisher":"American Chemical Society (ACS)","issue":"7","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R35 CA23213004"],"award-info":[{"award-number":["R35 CA23213004"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007052","name":"Memorial Sloan-Kettering Cancer Center","doi-asserted-by":"publisher","award":["AWD00004737"],"award-info":[{"award-number":["AWD00004737"]}],"id":[{"id":"10.13039\/100007052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015127","name":"Commonwealth Foundation for Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015127","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Disseminated melanoma, particularly of rare subtypes such as mucosal or uveal melanoma, is a difficult to treat, deadly disease characterized by poor median survival and resistance to a wide range of treatments. Despite new approvals, such as novel immunotherapeutics, there is a significant need for effective therapeutic modalities. Given the successes in the development of targeted radiopharmaceutical diagnostic agents and therapies for other cancers (the so-called theranostics), assessing the efficacy of these strategies in the context of melanoma appears as the next logical step. Here we aim to provide an overview of recent advances in the development of preclinical and clinical melanoma-specific radiopharmaceuticals. Where applicable, we will highlight their relevance in the context of rare subtypes of melanoma.<\/jats:p>","DOI":"10.1021\/acsptsci.5c00736","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T15:11:38Z","timestamp":1780672298000},"page":"1588-1600","source":"Crossref","is-referenced-by-count":0,"title":["Recent Developments in the Diagnosis and Treatment\nof Disseminated and Rare Melanoma with Radiotheranostics"],"prefix":"10.1021","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9415-382X","authenticated-orcid":true,"given":"Ru\u0308diger M.","family":"Exner","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center , , , ,","place":["New York, New York, United States, 10065"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7065-4534","authenticated-orcid":true,"given":"Jason S.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center , , , ,","place":["New York, New York, United States, 10065"]},{"name":"Memorial Sloan Kettering Cancer Center , , , ,","place":["New York, New York, United States, 10065"]},{"name":"Weill Cornell Medicine , , , ,","place":["New York, New York, United States, 10065"]},{"name":"Weill Cornell Medicine , , , ,","place":["New York, New York, United States, 10065"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6930-7383","authenticated-orcid":true,"given":"Lisa","family":"Bodei","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center , , , ,","place":["New York, New York, United States, 10065"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1750-7436","authenticated-orcid":true,"given":"Naga Vara Kishore","family":"Pillarsetty","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center , , , ,","place":["New York, New York, United States, 10065"]},{"name":"Weill Cornell Medicine , , , ,","place":["New York, New York, United States, 10065"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"issue":"9","key":"2026090715213711700_cit1","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1111\/jdv.12236","article-title":"Trends in incidence and predictions of cutaneous melanoma\nacross Europe up to 2015","volume":"28","author":"Arnold","year":"2014","journal-title":"J. Eur. Acad. Dermatol.\nVenereol."},{"issue":"5","key":"2026090715213711700_cit2","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol."},{"issue":"10","key":"2026090715213711700_cit3","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1002\/cam4.1152","article-title":"Survival of cutaneous\nmelanoma based on sex, age, and stage in the United States, 1992\u20132011","volume":"6","author":"Enninga","year":"2017","journal-title":"Cancer Med."},{"issue":"22","key":"2026090715213711700_cit4","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1200\/jco.19.03034","article-title":"Prognosis of Patients\nWith Stage III Melanoma According to American Joint Committee on Cancer\nVersion 8: A Reassessment on the Basis of 3 Independent Stage III\nMelanoma Cohorts","volume":"38","author":"Garbe","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"2026090715213711700_cit5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/pcmr.12885","article-title":"Acral lentiginous\nmelanoma: Basic facts, biological\ncharacteristics and research perspectives of an understudied disease","volume":"34","author":"Basurto-Lozada","year":"2021","journal-title":"Pigm. Cell Melanoma Res."},{"key":"2026090715213711700_cit6","doi-asserted-by":"publisher","DOI":"10.1177\/10732748211053567","article-title":"Acral Lentiginous\nMelanoma: A United States Multi-Center Substage Survival Analysis","volume":"28","author":"Kolla","year":"2021","journal-title":"Cancer Control"},{"issue":"11","key":"2026090715213711700_cit7","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s11912-023-01453-x","article-title":"Mucosal Melanoma:\nEpidemiology, Clinical\nFeatures, and Treatment","volume":"25","author":"Sergi","year":"2023","journal-title":"Curr. Oncol. Rep."},{"key":"2026090715213711700_cit8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15051356","article-title":"Current Trends in Mucosal Melanomas: An Overview","volume":"15","author":"Santeufemia","year":"2023","journal-title":"Cancers"},{"issue":"2","key":"2026090715213711700_cit9","doi-asserted-by":"publisher","DOI":"10.1016\/j.apjo.2024.100060","article-title":"Uveal melanoma:\nCurrent evidence on prognosis, treatment\nand potential developments","volume":"13","author":"Gelmi","year":"2024","journal-title":"Asia-Pacific J.\nOphthalmol."},{"issue":"1","key":"2026090715213711700_cit10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s40487-018-0056-8","article-title":"Uveal Melanoma: A Review\nof the Literature","volume":"6","author":"Singh","year":"2018","journal-title":"Oncol. Ther."},{"issue":"2","key":"2026090715213711700_cit11","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/ajcp\/aqad029","article-title":"Multiorgan\nInvolvement of Dormant Uveal Melanoma Micrometastases\nin Postmortem Tissue From Patients Without Coexisting Macrometastases","volume":"160","author":"Gill","year":"2023","journal-title":"Am. J. Clin. Pathol."},{"issue":"24","key":"2026090715213711700_cit12","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.1056\/NEJMoa2304753","article-title":"Three-Year\nOverall Survival with Tebentafusp in Metastatic\nUveal Melanoma","volume":"389","author":"Hassel","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"2026090715213711700_cit13","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100320","article-title":"Trends\nin survival and costs in metastatic melanoma in the era of novel targeted\nand immunotherapeutic drugs","volume":"6","author":"Franken","year":"2021","journal-title":"ESMO Open"},{"issue":"1","key":"2026090715213711700_cit14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2217\/mmt.15.38","article-title":"Biology\nand treatment of BRAF mutant\nmetastatic melanoma","volume":"3","author":"Kong","year":"2016","journal-title":"Melanoma Manage."},{"issue":"11","key":"2026090715213711700_cit15","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1007\/s11864-022-01006-7","article-title":"BRAF Inhibitor\nResistance in Melanoma: Mechanisms and\nAlternative Therapeutic Strategies","volume":"23","author":"Zhong","year":"2022","journal-title":"Curr. Treat.\nOptions Oncol."},{"issue":"1","key":"2026090715213711700_cit16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36979-y","article-title":"The molecular\nand functional landscape\nof resistance to immune checkpoint blockade in melanoma","volume":"14","author":"Lim","year":"2023","journal-title":"Nat. Commun."},{"issue":"6","key":"2026090715213711700_cit17","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1016\/j.ejca.2012.11.019","article-title":"Resistance to BRAF-targeted therapy\nin melanoma","volume":"49","author":"Sullivan","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"2026090715213711700_cit18","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrc3760","article-title":"Targeting RAF kinases\nfor cancer therapy: BRAF-mutated melanoma and beyond","volume":"14","author":"Holderfield","year":"2014","journal-title":"Nat. Rev. Cancer"},{"issue":"10304","key":"2026090715213711700_cit19","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune\ncheckpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"key":"2026090715213711700_cit20","doi-asserted-by":"publisher","DOI":"10.1177\/1758835920922028","article-title":"Immune checkpoint inhibitors\nin advanced or metastatic mucosal melanoma: a systematic review","volume":"12","author":"Li","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"5","key":"2026090715213711700_cit21","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s40123-024-00913-2","article-title":"The Future of Checkpoint\nInhibitors in Uveal Melanoma:\nA Narrative Review","volume":"13","author":"Wang","year":"2024","journal-title":"Ophthalmol. Ther."},{"issue":"1","key":"2026090715213711700_cit22","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-55675-5","article-title":"Immune checkpoint inhibitors for metastatic uveal melanoma:\na meta-analysis","volume":"14","author":"Yamada","year":"2024","journal-title":"Sci. Rep."},{"issue":"8","key":"2026090715213711700_cit23","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved Survival\nwith Ipilimumab in Patients with Metastatic Melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"2026090715213711700_cit24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.602705","article-title":"Immune Checkpoint Inhibitors\nin Advanced Acral Melanoma: A Systematic Review","volume":"10","author":"Zheng","year":"2020","journal-title":"Front. Oncol."},{"issue":"7","key":"2026090715213711700_cit25","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1007\/s11864-024-01212-5","article-title":"External Beam Radiotherapy\nin the Management of Uveal Melanoma","volume":"25","author":"Yilmaz","year":"2024","journal-title":"Curr. Treat.\nOptions Oncol."},{"key":"2026090715213711700_cit26","doi-asserted-by":"publisher","DOI":"10.1177\/1533033818798792","article-title":"SRS in Combination\nWith Ipilimumab: A Promising New\nDimension for Treating Melanoma Brain Metastases","volume":"17","author":"Khan","year":"2018","journal-title":"Technol. Cancer Res. Treat."},{"issue":"1","key":"2026090715213711700_cit27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2478\/v10019-010-0008-x","article-title":"Role of radiotherapy\nin melanoma management","volume":"44","author":"Strojan","year":"2010","journal-title":"Radiol. Oncol."},{"key":"2026090715213711700_cit28","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1200\/JCO.2025.43.16_suppl.3099","article-title":"Interim safety and efficacy data\nof [212Pb]VMT01 in MC1R expressing melanoma","volume":"43","author":"Morris","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"2026090715213711700_cit29","article-title":"Low-dose [212Pb]VMT01 targeted alpha-particle\ntherapy cooperates\nwith immune checkpoint inhibitors to induce robust tumor responses\nin a heterogeneous melanoma model in mice","volume":"65","author":"Rodman","year":"2024","journal-title":"J.\nNucl. Med."},{"issue":"13","key":"2026090715213711700_cit30","doi-asserted-by":"publisher","first-page":"6100","DOI":"10.7150\/thno.109243","article-title":"First-in-human PET imaging and evaluation\nof melanin-targeted [18F]DMPY2 in malignant melanoma patients","volume":"15","author":"Yang","year":"2025","journal-title":"Theranostics"},{"issue":"10","key":"2026090715213711700_cit31","doi-asserted-by":"publisher","first-page":"3062","DOI":"10.1007\/s00259-023-06258-5","article-title":"Melanin-targeted\n[18F]-PFPN PET imaging for prognosticating patients with melanoma","volume":"50","author":"Zhang","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"2026090715213711700_cit32","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-09495-3","article-title":"Phase I study\nof [131I] ICF01012, a targeted radionuclide therapy, in metastatic\nmelanoma: MELRIV-1 protocol","volume":"22","author":"Thivat","year":"2022","journal-title":"BMC Cancer"},{"key":"2026090715213711700_cit33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.critrevonc.2016.12.003","article-title":"Melanoma:\nLast call for radiotherapy","volume":"110","author":"Espenel","year":"2017","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"issue":"8","key":"2026090715213711700_cit34","first-page":"2561","article-title":"Cellular Radiosensitivity of Primary\nand Metastatic Human Uveal Melanoma Cell Lines","volume":"43","author":"van den Aardweg","year":"2002","journal-title":"Invest. Ophthalmol. Visual Sci."},{"issue":"1","key":"2026090715213711700_cit35","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/9435389","article-title":"Radiotherapy\nfor Melanoma: More than DNA Damage","volume":"2019","author":"Rogers","year":"2019","journal-title":"Dermatol.\nRes. Pract."},{"issue":"6","key":"2026090715213711700_cit36","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1002\/ijc.23664","article-title":"Inhibition of melanogenesis as a\nradiation sensitizer for melanoma therapy","volume":"123","author":"Broz\u0307yna","year":"2008","journal-title":"Int.\nJ. Cancer"},{"issue":"1","key":"2026090715213711700_cit37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2014.05.1040","article-title":"Local Control of Melanoma Brain Metastases\nby Metastatic Lesion","volume":"90","author":"Bagshaw","year":"2014","journal-title":"Int. J. Radiat. Oncol.\nBiol. Phys."},{"issue":"2","key":"2026090715213711700_cit38","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2021.100839","article-title":"Complete\nResponse\nAfter Stereotactic Body Radiation Therapy With Concurrent Immunotherapy\nfor Vaginal Melanoma","volume":"7","author":"Schonewolf","year":"2022","journal-title":"Adv. Radiat. Oncol."},{"issue":"4","key":"2026090715213711700_cit39","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/j.ijrobp.2023.01.017","article-title":"Concurrent Administration of Immune\nCheckpoint Inhibitors and Single Fraction Stereotactic Radiosurgery\nin Patients With Non-Small Cell Lung Cancer, Melanoma, and Renal Cell\nCarcinoma Brain Metastases","volume":"116","author":"Lehrer","year":"2023","journal-title":"Int. J. Radiat.\nOncol. Biol. Phys."},{"issue":"2","key":"2026090715213711700_cit40","doi-asserted-by":"publisher","DOI":"10.1097\/CCO.0000000000000818","article-title":"Recent advances\nin radiosensitivity\ndeterminants in melanoma","volume":"34","author":"Krayem","year":"2022","journal-title":"Curr. Opin. Oncol."},{"key":"2026090715213711700_cit41","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1200\/edbk_350946","article-title":"Predictors and Real-World Use of\nProstate-Specific\nRadioligand Therapy: PSMA and Beyond","volume":"42","author":"Gafita","year":"2022","journal-title":"Am. Soc.\nClin. Oncol. Educ. Book"},{"issue":"3","key":"2026090715213711700_cit42","first-page":"404","article-title":"Low Efficacy of 18F-FDG\nPET for Detection\nof Uveal Malignant Melanoma Compared with 123I-IMP SPECT","volume":"47","author":"Kato","year":"2006","journal-title":"J. Nucl. Med."},{"key":"2026090715213711700_cit43","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133147","article-title":"Imaging of\nUveal Melanoma\u2500Current Standard and Methods in Development","volume":"14","author":"Solnik","year":"2022","journal-title":"Cancers"},{"issue":"8","key":"2026090715213711700_cit44","doi-asserted-by":"publisher","first-page":"742","DOI":"10.3348\/kjr.2024.0243","article-title":"A Novel Melanin-Targeted\n18F-PFPN Positron Emission Tomography Imaging\nfor Diagnosing Ocular and Orbital Melanoma","volume":"25","author":"Wang","year":"2024","journal-title":"Korean J. Radiol."},{"issue":"10","key":"2026090715213711700_cit45","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.2967\/jnumed.121.263179","article-title":"18F-PFPN\nPET: A New and Attractive Imaging Modality for Patients with Malignant\nMelanoma","volume":"63","author":"Zhang","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"2","key":"2026090715213711700_cit46","doi-asserted-by":"publisher","first-page":"91","DOI":"10.22038\/aojnmb.2022.61517.1433","article-title":"Non-Cutaneous Melanoma, Findings\nand Prognostic Value\nof FDG PET\/CT: A Case Series of 23 patients and review of the literature","volume":"10","author":"Saidi","year":"2022","journal-title":"Asia Ocean. J. Nucl. Med. Biol."},{"issue":"8","key":"2026090715213711700_cit47","doi-asserted-by":"publisher","DOI":"10.1200\/PO.23.00702","article-title":"Melanocortin-1 Receptor\nExpression as a Marker of Progression in Melanoma","author":"Su","year":"2024","journal-title":"JCO Precis. Oncol."},{"issue":"8","key":"2026090715213711700_cit48","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.2967\/jnumed.118.217240","article-title":"Melanocortin 1 Receptor\u2013Targeted\n\u03b1-Particle Therapy for Metastatic Uveal Melanoma","volume":"60","author":"Tafreshi","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"3","key":"2026090715213711700_cit49","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1167\/iovs.06-0090","article-title":"Melanocortin\n1 Receptor Is Expressed\nby Uveal Malignant Melanoma and Can Be Considered a New Target for\nDiagnosis and Immunotherapy","volume":"48","author":"Lo\u0301pez","year":"2007","journal-title":"Invest. Ophthalmol.\nVisual Sci."},{"issue":"1","key":"2026090715213711700_cit50","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-45221-2","article-title":"CAR-T cell therapy targeting surface expression of\nTYRP1 to treat cutaneous and rare melanoma subtypes","volume":"15","author":"Jilani","year":"2024","journal-title":"Nat. Commun."},{"key":"2026090715213711700_cit51","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3233\/HAB-2007-163-407","article-title":"Generation and characterization\nof a therapeutic human antibody to melanoma antigen TYRP1","volume":"16","author":"Patel","year":"2008","journal-title":"Hum. Antibodies"},{"key":"2026090715213711700_cit52","article-title":"Development of Theranostic Radioimmunoconjugates against\nTyrosinase-related protein 1, a melanoma-specific antigen","volume":"66","author":"Exner","year":"2025","journal-title":"J. Nucl. Med."},{"issue":"21","key":"2026090715213711700_cit53","doi-asserted-by":"publisher","first-page":"5204","DOI":"10.1158\/1078-0432.CCR-16-1241","article-title":"An Open-Label, Dose\u2013Escalation\nPhase I Study of Anti-TYRP1Monoclonal Antibody IMC-20D7S for Patients\nwith Relapsed or Refractory Melanoma","volume":"22","author":"Khalil","year":"2016","journal-title":"Clin.\nCancer Res."},{"key":"2026090715213711700_cit54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1346502","article-title":"Phase 1, first-in-human study of\nTYRP1-TCB (RO7293583), a novel TYRP1-targeting CD3 T-cell engager,\nin metastatic melanoma: active drug monitoring to assess the impact\nof immune response on drug exposure","volume":"14","author":"Spreafico","year":"2024","journal-title":"Front.\nOncol."},{"issue":"5","key":"2026090715213711700_cit55","doi-asserted-by":"publisher","first-page":"785","DOI":"10.2967\/jnumed.124.268857","article-title":"MHC-I\u2013Driven Antitumor Immunity\nCounterbalances Low Absorbed Doses of Radiopharmaceutical Therapy","volume":"66","author":"Constanzo","year":"2025","journal-title":"J. Nucl. Med."},{"issue":"29","key":"2026090715213711700_cit56","doi-asserted-by":"publisher","first-page":"24082","DOI":"10.1074\/jbc.M112.361485","article-title":"The Melanosomal Protein\nPMEL17 as\na Target for Antibody Drug Conjugate Therapy in Melanoma","volume":"287","author":"Chen","year":"2012","journal-title":"J. Biol. Chem."},{"issue":"1","key":"2026090715213711700_cit57","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-02334-y","article-title":"First-in-human\ndosimetry and safety evaluation of 68Ga-\u03b1MSH derivative for\nPET imaging of melanoma","volume":"15","author":"Zolghadri","year":"2025","journal-title":"Sci. Rep."},{"key":"2026090715213711700_cit58","doi-asserted-by":"publisher","DOI":"10.1016\/j.nucmedbio.2024.108925","article-title":"Preclinical evaluation of MC1R targeting\ntheranostic pair [155Tb]Tb-crown-\u03b1MSH and [161Tb]Tb-crown-\u03b1MSH","volume":"136\u2013137","author":"Wharton","year":"2024","journal-title":"Nucl. Med. Biol."},{"issue":"19","key":"2026090715213711700_cit59","doi-asserted-by":"publisher","first-page":"10767","DOI":"10.1021\/acsomega.0c00310","article-title":"Selective\nCyclized \u03b1-Melanocyte-Stimulating Hormone\nDerivative with Multiple N-Methylations for Melanoma Imaging with\nPositron Emission Tomography","volume":"5","author":"Zhang","year":"2020","journal-title":"ACS Omega"},{"issue":"4","key":"2026090715213711700_cit60","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1021\/acs.molpharmaceut.9b00025","article-title":"Evaluation\nof a Novel Pb-203-Labeled Lactam-Cyclized Alpha-Melanocyte-Stimulating\nHormone Peptide for Melanoma Targeting","volume":"16","author":"Yang","year":"2019","journal-title":"Mol.\nPharmaceutics"},{"issue":"8","key":"2026090715213711700_cit61","doi-asserted-by":"publisher","first-page":"4004","DOI":"10.1021\/acs.molpharmaceut.4c00369","article-title":"Effect of\nIbuprofen as an Albumin Binder on Melanoma-Targeting Properties\nof 177Lu-Labeled Ibuprofen-Conjugated Alpha-Melanocyte-Stimulating\nHormone Peptides","volume":"21","author":"Qiao","year":"2024","journal-title":"Mol. Pharmaceutics"},{"issue":"1","key":"2026090715213711700_cit62","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-50014-5","article-title":"18F-Labeled\nCyclized \u03b1-Melanocyte-Stimulating Hormone Derivatives for Imaging\nHuman Melanoma Xenograft with Positron Emission Tomography","volume":"9","author":"Zhang","year":"2019","journal-title":"Sci. Rep."},{"issue":"6","key":"2026090715213711700_cit63","doi-asserted-by":"publisher","first-page":"2107","DOI":"10.1007\/s00259-024-07056-3","article-title":"An 211At-labeled\nalpha-melanocyte\nstimulating hormone peptide analog for targeted alpha therapy of metastatic\nmelanoma","volume":"52","author":"Suzuki","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"3","key":"2026090715213711700_cit64","doi-asserted-by":"publisher","first-page":"313","DOI":"10.2967\/jnumed.120.243840","article-title":"Advances in Receptor-Targeted Radiolabeled Peptides\nfor Melanoma Imaging and Therapy","volume":"62","author":"Miao","year":"2021","journal-title":"J. Nucl. Med."},{"key":"2026090715213711700_cit65","doi-asserted-by":"publisher","DOI":"10.3390\/molecules30102095","article-title":"NOTA and\nNODAGA Radionuclide Complexing Agents: Versatile Approaches for Advancements\nin Radiochemistry","volume":"30","author":"Chambers","year":"2025","journal-title":"Molecules"},{"issue":"4","key":"2026090715213711700_cit66","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/sj.bjc.6600441","article-title":"Tissue distribution\nand differential expression of melanocortin 1 receptor, a malignant\nmelanoma marker","volume":"87","author":"Salazar-Onfray","year":"2002","journal-title":"Br. J. Cancer"},{"issue":"15","key":"2026090715213711700_cit67","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241512152","article-title":"Melanocortin\n1 Receptor (MC1R): Pharmacological and\nTherapeutic Aspects","volume":"24","author":"Mun","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"2026090715213711700_cit68","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1080\/17512433.2021.1879638","article-title":"Afamelanotide for prevention of phototoxicity\nin erythropoietic protoporphyria","volume":"14","author":"Wensink","year":"2021","journal-title":"Expert Rev.\nClin. Pharmacol."},{"issue":"20","key":"2026090715213711700_cit69","first-page":"5649","article-title":"Melanoma-targeting\nProperties of 99mTechnetium-labeled Cyclic \u03b1-Melanocyte-stimulating\nHormone Peptide Analogues1","volume":"60","author":"Chen","year":"2000","journal-title":"Cancer Res."},{"issue":"12","key":"2026090715213711700_cit70","first-page":"1847","article-title":"Evaluation\nof an 111In-DOTA\u2013Rhenium\nCyclized \u03b1-MSH Analog: A Novel Cyclic-Peptide Analog with Improved\nTumor-Targeting Properties","volume":"42","author":"Chen","year":"2001","journal-title":"J. Nucl. Med."},{"issue":"5","key":"2026090715213711700_cit71","doi-asserted-by":"publisher","first-page":"4007","DOI":"10.1021\/acs.jmedchem.1c01848","article-title":"CLIPSing Melanotan-II to Discover\nMultiple Functionally Selective hMCR Agonists","volume":"65","author":"Tomassi","year":"2022","journal-title":"J. Med. Chem."},{"issue":"466","key":"2026090715213711700_cit72","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau4445","article-title":"68Ga-DOTA-GGNle-CycMSHhex\ntargets the melanocortin-1 receptor for\nmelanoma imaging","volume":"10","author":"Yang","year":"2018","journal-title":"Sci. Transl. Med."},{"issue":"9","key":"2026090715213711700_cit73","doi-asserted-by":"publisher","first-page":"3904","DOI":"10.1021\/acs.molpharmaceut.9b00512","article-title":"Enhancing the Efficacy\nof Melanocortin 1 Receptor-Targeted Radiotherapy by Pharmacologically\nUpregulating the Receptor in Metastatic Melanoma","volume":"16","author":"Li","year":"2019","journal-title":"Mol. Pharmaceutics"},{"key":"2026090715213711700_cit74","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS9612","article-title":"First-in-human study\nof 225actinium\nmti-201 (225Ac-MTI-201) in metastatic uveal melanoma (UM)","volume":"42","author":"Khushalani","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"2026090715213711700_cit75","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.ejps.2017.06.026","article-title":"Preclinical evaluation of melanocortin-1\nreceptor (MC1-R) specific 68Ga- and 44Sc-labeled DOTA-NAPamide in\nmelanoma imaging","volume":"106","author":"Nagy","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"issue":"1","key":"2026090715213711700_cit76","first-page":"116","article-title":"A Gallium-Labeled DOTA-\u03b1-Melanocyte-\nStimulating Hormone Analog for PET Imaging of Melanoma Metastases","volume":"45","author":"Froidevaux","year":"2004","journal-title":"J. Nucl. Med."},{"issue":"6","key":"2026090715213711700_cit77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217883","article-title":"Increasing molar activity by HPLC\npurification improves 68Ga-DOTA-NAPamide tumor accumulation in a B16\/F1\nmelanoma xenograft model","volume":"14","author":"von Hacht","year":"2019","journal-title":"PLoS One"},{"issue":"2","key":"2026090715213711700_cit78","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1021\/acsptsci.1c00035","article-title":"Lipophilicity Determines\nRoutes of Uptake and Clearance, and Toxicity of an Alpha-Particle-Emitting\nPeptide Receptor Radiotherapy","volume":"4","author":"Tafreshi","year":"2021","journal-title":"ACS Pharmacol.\nTransl. Sci."},{"issue":"4","key":"2026090715213711700_cit79","doi-asserted-by":"publisher","first-page":"805","DOI":"10.7150\/thno.17117","article-title":"Preclinical\nMelanoma Imaging with 68Ga-Labeled \u03b1-Melanocyte-Stimulating\nHormone Derivatives Using PET","volume":"7","author":"Zhang","year":"2017","journal-title":"Theranostics"},{"issue":"3","key":"2026090715213711700_cit80","doi-asserted-by":"publisher","first-page":"418","DOI":"10.2967\/jnumed.109.071787","article-title":"Reduction of the Ring\nSize of Radiolabeled Lactam Bridge\u2013Cyclized \u03b1-MSH Peptide,\nResulting in Enhanced Melanoma Uptake","volume":"51","author":"Guo","year":"2010","journal-title":"J. Nucl.\nMed."},{"issue":"4","key":"2026090715213711700_cit81","doi-asserted-by":"publisher","first-page":"608","DOI":"10.2967\/jnumed.110.086009","article-title":"Effects of the Amino\nAcid Linkers on the Melanoma-Targeting and Pharmacokinetic Properties\nof 111In-Labeled Lactam Bridge\u2013Cyclized \u03b1-MSH\nPeptides","volume":"52","author":"Guo","year":"2011","journal-title":"J. Nucl. Med."},{"key":"2026090715213711700_cit82","article-title":"111In-labeled\nMC1R-targeting\npeptide with a renal brush border enzyme-cleavable linkage for low\nrenal radioactivity levels","volume":"64","author":"Suzuki","year":"2023","journal-title":"J. Nucl. Med."},{"key":"2026090715213711700_cit83","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.1196","article-title":"1128P Preliminary results\nof first-in-human\nstudy of 225-Actinium MTI-201 (225Ac-MTI-201) in metastatic uveal\nmelanoma","volume":"35","author":"Khushalani","year":"2024","journal-title":"Ann. Oncol."},{"issue":"2","key":"2026090715213711700_cit84","doi-asserted-by":"publisher","first-page":"318","DOI":"10.2967\/jnumed.107.045054","article-title":"Bombesin\nReceptor\nAntagonists May Be Preferable to Agonists for Tumor Targeting","volume":"49","author":"Cescato","year":"2008","journal-title":"J. Nucl. Med."},{"key":"2026090715213711700_cit85","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225766","article-title":"Radiolabeled Bombesin\nAnalogs","volume":"13","author":"Mansi","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"2026090715213711700_cit86","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/j.0022-202X.2004.23444.x","article-title":"Pharmacological\nCharacterization of Loss of Function\nMutations of the Human Melanocortin 1 Receptor That Are Associated\nwith Red Hair","volume":"123","author":"Ringholm","year":"2004","journal-title":"J. Invest. Dermatol."},{"issue":"5","key":"2026090715213711700_cit87","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/pcmr.12951","article-title":"Human TYRP1: Two functions for a single gene?","volume":"34","author":"Gautron","year":"2021","journal-title":"Pigm. Cell Melanoma Res."},{"issue":"33","key":"2026090715213711700_cit88","doi-asserted-by":"publisher","first-page":"9812","DOI":"10.1002\/anie.201704616","article-title":"Structure of Human\nTyrosinase Related Protein 1 Reveals a Binuclear Zinc Active Site\nImportant for Melanogenesis","volume":"56","author":"Lai","year":"2017","journal-title":"Angew. Chem., Int.\nEd."},{"issue":"2","key":"2026090715213711700_cit89","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.molonc.2011.01.006","article-title":"Tyrosinase related protein 1 (TYRP1\/gp75) in human\ncutaneous melanoma","volume":"5","author":"Ghanem","year":"2011","journal-title":"Mol. Oncol."},{"issue":"1","key":"2026090715213711700_cit90","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-023-04640-5","article-title":"Pigmentation and TYRP1\nexpression are mediated by zinc through the\nearly secretory pathway-resident ZNT proteins","volume":"6","author":"Wagatsuma","year":"2023","journal-title":"Commun. Biol."},{"issue":"11","key":"2026090715213711700_cit91","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1038\/bjc.2011.451","article-title":"TYRP1 mRNA\nexpression in melanoma metastases correlates with clinical outcome","volume":"105","author":"Journe","year":"2011","journal-title":"Br. J. Cancer."},{"issue":"12","key":"2026090715213711700_cit92","doi-asserted-by":"publisher","first-page":"4200","DOI":"10.1073\/pnas.84.12.4200","article-title":"Monoclonal\nantibody to an intracellular antigen images\nhuman melanoma transplants in nu\/nu mice","volume":"84","author":"Welt","year":"1987","journal-title":"Proc.\nNatl. Acad. Sci. U.S.A."},{"key":"2026090715213711700_cit93","doi-asserted-by":"publisher","first-page":"19S","DOI":"10.2967\/jnumed.123.266945","article-title":"Melanin-Targeting\nRadiotracers and Their Preclinical, Translational, and Clinical Status:\nFrom Past to Future","volume":"65","author":"Zhang","year":"2024","journal-title":"J. Nucl. Med."},{"key":"2026090715213711700_cit94","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.887366","article-title":"The Dark\nSide of\nMelanin Secretion in Cutaneous Melanoma Aggressiveness","author":"Cabac\u0327o","year":"2022","journal-title":"Front. Oncol."},{"issue":"12","key":"2026090715213711700_cit95","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/j.nucmedbio.2016.08.010","article-title":"[18F]MEL050\nas a melanin-targeted PET tracer: Fully automated radiosynthesis and\ncomparison to 18F-FDG for the detection of pigmented melanoma in mice\nprimary subcutaneous tumors and pulmonary metastases","volume":"43","author":"Rizzo-Padoin","year":"2016","journal-title":"Nucl. Med. Biol."},{"issue":"23","key":"2026090715213711700_cit96","doi-asserted-by":"publisher","first-page":"12991","DOI":"10.1073\/pnas.1922313117","article-title":"Ultrasensitive\ndetection of malignant melanoma using PET molecular imaging probes","volume":"117","author":"Pyo","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"s2","key":"2026090715213711700_cit97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1600-0773.1972.tb03310.x","article-title":"The Melanin Affinity\nof Chloroquine and Chlorpromazine\nStudied by Whole Body Autoradiography","volume":"31","author":"Lindquist","year":"1972","journal-title":"Acta\nPharmacol. Toxicol."},{"issue":"1","key":"2026090715213711700_cit98","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1001\/jama.1968.03150010045009","article-title":"Visualizing Human\nMalignant Melanoma and Metastases: Use of Chloroquine Analog Tagged\nWith Iodine 125","volume":"206","author":"Beierwaltes","year":"1968","journal-title":"JAMA"},{"key":"2026090715213711700_cit99","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107829","article-title":"Benzamide\nderivative radiotracers targeting melanin for melanoma imaging and\ntherapy: Preclinical\/clinical development and combination with other\ntreatments","volume":"224","author":"Rouanet","year":"2021","journal-title":"Pharmacol. Ther."},{"issue":"16","key":"2026090715213711700_cit100","doi-asserted-by":"publisher","first-page":"4915","DOI":"10.1016\/j.bmc.2012.06.047","article-title":"Synthesis\nand characterization\nof a 68Ga-labeled N-(2-diethylaminoethyl)benzamide derivative as potential\nPET Probe for malignant melanoma","volume":"20","author":"Kim","year":"2012","journal-title":"Bioorg. Med.\nChem."},{"issue":"2","key":"2026090715213711700_cit101","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1021\/acs.molpharmaceut.2c00745","article-title":"Synthesis and Preclinical\nEvaluation of a 68Ga-Labeled Pyridine-Based Benzamide Dimer for Malignant\nMelanoma Imaging","volume":"20","author":"Wang","year":"2023","journal-title":"Mol. Pharmaceutics"},{"issue":"1","key":"2026090715213711700_cit102","first-page":"127","article-title":"Pharmacokinetics\nof Iodine-123-IMBA for Melanoma Imaging","volume":"38","author":"Nicholl","year":"1997","journal-title":"J.\nNucl. Med."},{"issue":"7","key":"2026090715213711700_cit103","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.nucmedbio.2008.05.011","article-title":"Synthesis and evaluation of novel radioiodinated nicotinamides\nfor malignant melanoma","volume":"35","author":"Liu","year":"2008","journal-title":"Nucl. Med. Biol."},{"issue":"6","key":"2026090715213711700_cit104","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/0969-8051(95)00020-X","article-title":"Synthesis,\nradiolabeling, and preliminary evaluation in mice of some (N-Diethylaminoethyl)-4-iodobenzamide\nderivatives as melanoma imaging agents","volume":"22","author":"Moreau","year":"1995","journal-title":"Nucl.\nMed. Biol."},{"issue":"8","key":"2026090715213711700_cit105","first-page":"1573","article-title":"Synthesis\nand Evaluation of New Iodine-125 Radiopharmaceuticals as Potential\nTracers for Malignant Melanoma","volume":"32","author":"Michelot","year":"1991","journal-title":"J. Nucl. Med."},{"issue":"9","key":"2026090715213711700_cit106","doi-asserted-by":"publisher","first-page":"3384","DOI":"10.1021\/mp400225s","article-title":"A Novel Aliphatic\n18F-Labeled Probe\nfor PET Imaging of Melanoma","volume":"10","author":"Liu","year":"2013","journal-title":"Mol. Pharmaceutics"},{"issue":"5","key":"2026090715213711700_cit107","doi-asserted-by":"publisher","first-page":"827","DOI":"10.2967\/jnumed.116.184564","article-title":"4-11C-Methoxy N-(2-Diethylaminoethyl)\nBenzamide: A Novel Probe to Selectively Target Melanoma","volume":"58","author":"Garg","year":"2017","journal-title":"J. Nucl. Med."},{"key":"2026090715213711700_cit108","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.ejmech.2012.02.014","article-title":"99mTc(I)\/Re(I)\ntricarbonyl complexes for in vivo targeting of melanotic melanoma:\nSynthesis and biological evaluation","volume":"50","author":"Moura","year":"2012","journal-title":"Eur. J.\nMed. Chem."},{"issue":"1","key":"2026090715213711700_cit109","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1034\/j.1600-0420.1998.760110.x","article-title":"Clinical study\nof [123I] N-(2-diethylaminoethyl)-4- iodobenzamide in the diagnosis\nof primary and metastatic ocular melanoma","volume":"76","author":"Bacin","year":"1998","journal-title":"Acta\nOphthalmol. Scand."},{"issue":"1","key":"2026090715213711700_cit110","doi-asserted-by":"publisher","first-page":"16","DOI":"10.2967\/jnumed.118.209643","article-title":"Biodistribution, Radiation Dosimetry,\nand Clinical Application of\na Melanin-Targeted PET Probe, 18F-P3BZA, in Patients","volume":"60","author":"Ma","year":"2019","journal-title":"J. Nucl. Med."},{"key":"2026090715213711700_cit111","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1007\/s11307-025-02025-0","article-title":"Poor Diagnostic Performance of the\nMelanin-Binding Tracer [18 F]MEL050 in Human Melanoma Indicates Biological\nHeterogeneity","volume":"27","author":"Ware","year":"2025","journal-title":"Mol. Imaging Biol."},{"issue":"1","key":"2026090715213711700_cit112","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-018-0983-0","article-title":"Targeted radiotherapy\nof pigmented melanoma with 131I-5-IPN","volume":"37","author":"Xu","year":"2018","journal-title":"J. Exp.\nClin. Cancer Res."},{"issue":"10","key":"2026090715213711700_cit113","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.1158\/0008-5472.CAN-09-4414","article-title":"Preclinical Evaluation of an 131I-Labeled Benzamide\nfor Targeted Radiotherapy of Metastatic Melanoma","volume":"70","author":"Joyal","year":"2010","journal-title":"Cancer Res."},{"issue":"6","key":"2026090715213711700_cit114","doi-asserted-by":"publisher","DOI":"10.3390\/pr13061636","article-title":"A Simple Method to Determine Pheomelanin\nContent and Structure in FFPE Human Melanoma Specimens","volume":"13","author":"Kurkiewicz","year":"2025","journal-title":"Processes"},{"issue":"6","key":"2026090715213711700_cit115","doi-asserted-by":"publisher","DOI":"10.1002\/VIW.20240055","article-title":"Mucin 18-targeted humanized\nmonoclonal antibody immune positron emission tomography imaging and\npatient-derived tumor xenograft visualization","volume":"5","author":"Zhang","year":"2024","journal-title":"View"},{"issue":"2","key":"2026090715213711700_cit116","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1021\/acs.molpharmaceut.7b00961","article-title":"PET Imaging of VCAM-1 Expression and Monitoring Therapy Response\nin Tumor with a 68Ga-Labeled Single Chain Variable Fragment","volume":"15","author":"Zhang","year":"2018","journal-title":"Mol. Pharmaceutics"},{"issue":"11","key":"2026090715213711700_cit117","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.2967\/jnumed.114.144881","article-title":"PET Imaging of Very\nLate Antigen-4\nin Melanoma: Comparison of 68Ga- and 64Cu-Labeled\nNODAGA and CB-TE1A1P-LLP2A Conjugates","volume":"55","author":"Beaino","year":"2014","journal-title":"J. Nucl.\nMed."},{"key":"2026090715213711700_cit118","doi-asserted-by":"publisher","first-page":"48","DOI":"10.7150\/thno\/v01p0048","article-title":"PET Imaging\nof Integrin \u03b1V\u03b23 Expression","volume":"1","author":"Beer","year":"2011","journal-title":"Theranostics"},{"issue":"4","key":"2026090715213711700_cit119","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041193","article-title":"The Superiority of Fibroblast Activation Protein Inhibitor (FAPI)\nPET\/CT Versus FDG PET\/CT in the Diagnosis of Various Malignancies","volume":"15","author":"Dong","year":"2023","journal-title":"Cancers"},{"issue":"7","key":"2026090715213711700_cit120","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1007\/s00259-022-05702-2","article-title":"[68 Ga]Ga-FAPI versus [18F]F-FDG\nin malignant melanoma: complementary or counterpoint?","volume":"49","author":"Mokoala","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"2","key":"2026090715213711700_cit121","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/RLU.0000000000003882","article-title":"Increased\n68Ga-FAPI Activity in Malignant Melanoma of the Nasal Cavity","volume":"47","author":"Ou","year":"2022","journal-title":"Clin. Nucl. Med."},{"issue":"1","key":"2026090715213711700_cit122","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00259-8","article-title":"CD146, from a melanoma cell adhesion\nmolecule to a\nsignaling receptor","volume":"5","author":"Wang","year":"2020","journal-title":"Signal Transduction Targeted\nTher."},{"issue":"9","key":"2026090715213711700_cit123","doi-asserted-by":"publisher","first-page":"4490","DOI":"10.1021\/acs.molpharmaceut.4c00348","article-title":"Preclinical ImmunoPET Imaging Using a Zr-89-Labeled\nAnti-CD146 Monoclonal Antibody for Diagnosis of Melanoma","volume":"21","author":"Guo","year":"2024","journal-title":"Mol. Pharmaceutics"},{"issue":"12","key":"2026090715213711700_cit124","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.2967\/jnumed.118.209510","article-title":"Combined\nVLA-4\u2013Targeted Radionuclide Therapy and Immunotherapy in a\nMouse Model of Melanoma","volume":"59","author":"Choi","year":"2018","journal-title":"J. Nucl. Med."},{"issue":"6","key":"2026090715213711700_cit125","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1021\/mp5006917","article-title":"Evaluation of 68Ga-\nand 177Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment\nof Metastatic Melanoma","volume":"12","author":"Beaino","year":"2015","journal-title":"Mol. Pharmaceutics"},{"issue":"6","key":"2026090715213711700_cit126","doi-asserted-by":"publisher","first-page":"2960","DOI":"10.1021\/acs.molpharmaceut.4c00095","article-title":"Albumin-Binding\nLutetium-177-Labeled LLP2A Derivatives as Theranostics for Melanoma","volume":"21","author":"Pun","year":"2024","journal-title":"Mol. Pharmaceutics"},{"issue":"6","key":"2026090715213711700_cit127","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI\nPET\/CT: Tracer Uptake in 28 Different Kinds of Cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J. Nucl. Med."},{"key":"2026090715213711700_cit128","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1352615","article-title":"Comprehensive analysis\nof fibroblast activation protein expression\nacross 23 tumor indications: insights for biomarker development in\ncancer immunotherapies","volume":"15","author":"Dziadek","year":"2024","journal-title":"Front. Immunol."},{"issue":"14","key":"2026090715213711700_cit129","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1158\/0008-5472.CAN-15-2973","article-title":"FAP Promotes Immunosuppression by Cancer-Associated Fibroblasts in\nthe Tumor Microenvironment via STAT3\u2013CCL2 Signaling","volume":"76","author":"Yang","year":"2016","journal-title":"Cancer Res."},{"issue":"4","key":"2026090715213711700_cit130","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s002680020102","article-title":"Distribution and Functional\nSignificance of Somatostatin Receptors in Malignant Melanoma","volume":"25","author":"Lum","year":"2001","journal-title":"World J. Surg."},{"issue":"6","key":"2026090715213711700_cit131","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1089\/108497803322702860","article-title":"In Vivo\nand In Vitro Detection of Dopamine D2 Receptors in Uveal Melanomas","volume":"18","author":"Bodei","year":"2003","journal-title":"Cancer Biother. Radiopharm."}],"container-title":["ACS Pharmacology &amp; Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsptsci.5c00736","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/aptsfn\/article-pdf\/9\/7\/1588\/65855275\/acsptsci.5c00736.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/aptsfn\/article-pdf\/9\/7\/1588\/65855275\/acsptsci.5c00736.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T19:23:12Z","timestamp":1788808992000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/aptsfn\/article\/9\/7\/1588\/5205422\/Recent-Developments-in-the-Diagnosis-and-Treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":131,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,6,5]]},"published-print":{"date-parts":[[2026,7,10]]}},"URL":"https:\/\/doi.org\/10.1021\/acsptsci.5c00736","relation":{},"ISSN":["2575-9108"],"issn-type":[{"value":"2575-9108","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]}}}